2022 Attendees:

What You Missed at the 3rd TIGIT Axis Therapies Digital Summit

Preclinical and clinical data continues to demonstrate that the TIGIT axis blockade, particularly in combination with other immune checkpoint inhibitor partners, has strong efficacy. Despite recent clinical setbacks, and with at least 15 anti-TIGIT axis drugs in active clinical development, TIGIT axis targeting remains a promising treatment approach.

The 3rd TIGIT Axis Therapies Summit reunited large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting.

Covering deciphering the mechanistic intricacies underlying TIGIT axis signaling, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines, exploring novel drug designs in terms of Fc functionality and IgG type, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design, this is your guide to addressing the unique challenges of TIGIT axis targeted drug development.

This year’s sharp two-day agenda leaned into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups, join the conversation to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs.

View the 2022 agenda now

View the 2022 Agenda Now!

TIGIT Axis Therapies Event Guide Cover

Download your copy to see all the 2022 speakers, full agenda breakdown, partners and how you can access the best possible rates.

World-Class Speaker Faculty Included: